Evrysdi (Risdiplam) receives positive CHMP opinion for spinal muscular atrophy (SMA) treatment . The first only oral treatment at home for patients with spinal muscular atrophy

We received a great pressrelease from Roche. Risdiplam is a milestone ahead.   Basel, 26 February 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of EvrysdiTM (risdiplam) for the treatment of 5q spinal muscular atrophy… Fortsätt läsa Evrysdi (Risdiplam) receives positive CHMP opinion for spinal muscular atrophy (SMA) treatment . The first only oral treatment at home for patients with spinal muscular atrophy